Crossmark

[Artículo traducido] Análisis costes-efectividad del tocilizumab biosimilar subcutáneo en pacientes con artritis reumatoide en España

Crossref DOI link: https://doi.org/10.1016/j.farma.2025.02.006

Published Print: 2025-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Pérez-Ruiz, Fernando

Crespo-Diz, Carlos

Schoenenberger-Arnaiz, Joan Antoni

Cerezales, Mónica

Crespo, Carlos

Guigini, Marcelo Alejandro

Peinado-Fabregat, José Ignacio

Climente-Martí, Mónica
License Information

Text and Data Mining valid from 2025-09-01

Text and Data Mining valid from 2025-09-01

Version of Record valid from 2025-02-14
More Information

This article is maintained by: Elsevier

Article Title: [Artículo traducido] Análisis costes-efectividad del tocilizumab biosimilar subcutáneo en pacientes con artritis reumatoide en España

Journal Title: Farmacia Hospitalaria

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.farma.2025.02.006

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.farma.2024.11.004

Content Type: article

Copyright: © 2024 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U.